News

SCOHIA initiates a phase 2 proof of concept study on an enteropeptidase inhibitor (SCO-792) for diabetic kidney disease

Pipeline Information has been updated.

SCOHIA initiates a Phase1 study of a GPR40 full agonist (SCO-267)

SCOHIA initiates a phase 2 proof of concept study of an enteropeptidase inhibitor (SCO-792) in type 2 diabetes mellitus patients with obesity

SCOHIA and SEEDSUPPLY Announce Research Collaboration Agreement

Publication regarding the compound profiles of SCO-792,a novel enteropeptidase inhibitor

Presentation of New Preclinical Data of SCO-267, a GPR40 agonist, at The American Diabetes Association’s 79th Scientific Sessions

Publication regarding a preclinical study of SCO-267,a novel GPR40 agonist

Publication regarding preclinical studies of SCO-792, a novel enteropeptidase inhibitor

Publication regarding Imarikiren (SCO-272)